Auris Medical Holding AG (EARS) Trading Up 1%
Auris Medical Holding AG (NASDAQ:EARS)’s share price was up 1% during mid-day trading on Friday . The stock traded as high as $2.08 and last traded at $2.05, with a volume of 386,997 shares changing hands. The stock had previously closed at $2.03.
Several equities analysts have recently issued reports on EARS shares. Zacks Investment Research upgraded Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research note on Tuesday, July 12th. Leerink Swann reiterated a “buy” rating and issued a $12.00 price objective on shares of Auris Medical Holding AG in a research note on Wednesday, June 15th. Jefferies Group reiterated a “buy” rating on shares of Auris Medical Holding AG in a research note on Friday, June 10th. Needham & Company LLC lifted their price objective on Auris Medical Holding AG from $5.00 to $11.00 and gave the company a “buy” rating in a research note on Friday, August 19th. Finally, JMP Securities cut Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 18th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Auris Medical Holding AG presently has an average rating of “Buy” and a consensus target price of $8.88.
The firm’s market cap is $71.06 million. The firm has a 50 day moving average of $3.68 and a 200 day moving average of $3.86.
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.